Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet.
Total second-quarter revenue rose 6% fro
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its
PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors.
Pacira BioSciences (PCRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares were flat post-release as investors weighed the performance. The company highlighted progress in its non-opioid pain portfolio and gene therapy pipeline.
PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors.
PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability, steady growth, and reasonable financial health, making it a candidate for value investors.
